Sequentify Announces Research Grants for High-Throughput Genomic Studies

We invite proposals from research groups conducting genomic DNA studies using human-derived samples, regardless of research field. Eligible areas include, but are not limited to: oncology, rare disease, reproductive health, infectious disease, population screening, and public health.
To qualify, proposed studies must:
- Involve 5,000 human samples or more
- Require Sequentify's off-the-shelf or customized panels (up to 10,000 genomic targets)
Selected applicants will receive:
- Reagents for up to 10,000 samples
- Access to Sequentify's end-to-end analysis software
Submission Guidelines: In up to 250 words, describe how this grant would enhance your research and contribute to your scientific field.
Application period: April 5 –
Submit applications to: [email protected]
If you have questions about the grant or your project's eligibility, feel free to reach out to us at the same address—we'd be happy to help.
About Sequentify:
Founded in 2021 as a Weizmann Institute spinoff, Sequentify enables decentralized, population-wide genomic sequencing by providing laboratories with the easiest and quickest solutions available. Their technology facilitates the scaling-up of genomic testing by directly addressing the current pain points in the industry, through sample-prep and software solutions. The company offers panels for oncology and screening applications, and infectious diseases, with a focus on the clinical market. Sequentify is based in
Media Contact:
[email protected]
Logo: https://mma.prnewswire.com/media/2269535/SEQUENTIFY_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/sequentify-announces-research-grants-for-high-throughput-genomic-studies-302431271.html
SOURCE Sequentify
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Apex Institute Explains Why Skilled Engineers Still Fail Technical Interviews
- Best Crypto Presale: AlphaPepe at $0.02789 Keeps the $1 Roadmap Trade Alive With Public Trading Still Ahead
- Additional Information on the Ehrmann Family Increasing Its Equity Stake in Artprice by Artmarket as Part of Artprice's "AI-First" Transformation
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share